A pipeline rich in possibilities

Our portfolio of FTD and ALS gene therapies combine our neuroanatomy-led approach with proprietary AAV gene supplementation and silencing platforms. We are focused on targeted and precise drug delivery and dosing for maximal biodistribution to the brain and spinal cord with a favorable safety profile. We believe delivery to be the gamechanger in overcoming challenges with existing treatment pathways.